Expert Advice 14 Jun 2024
Biotech valuation multiples: how to value a biotech company?
How do biotech valuations based on multiples work? Experts share their most reliable methods to find the right price for a company’s stocks.
Regulatory approval
- Latest Posts
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
In Depth 15 Apr 2024
Does the FDA need to tighten its grip on drug trials in the U.S.?
Studies suggest that the FDA has been less rigorous with its drug approval standards. We looked at the current state of the approval process.
In Depth 21 Mar 2024
Biotech in France: What’s holding back progress and how to move forward?
Explore the latest insights from France Biotech’s ‘Panorama France HealthTech’ report, uncovering key insights of the French biotech sector.
Expert Advice 15 Mar 2024
Is biotechnology a good career? Here are the pros and cons
Find out about the pros and cons of pursuing a career in biotechnology, from competitive salaries to dealing with regulatory hurdles.
News and Trends 28 Jul 2023
FDA grants breakthrough therapy designation to Duchenne muscular dystrophy treatment
The U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS Pharma Inc.’s NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy. The breakthrough designation is based on results from a first-in-human, investigator-initiated clinical trial conducted in Japan. In June 2023, NS-089/NCNP-02 was granted Rare […]
ADVERTISEMENT
ADVERTISEMENT
Expert Advice 28 Jul 2023
What you need to know about the EU HTA regulation before deadline
By Anke van Engen, senior principal, EMEA value & payer evidence, IQVIA, and Dima Samaha, senior principal, EMEA value & payer evidence, IQVIA The European Union (EU) comprises 27 member states (MS) with varying laws, processes and regulatory standards. This variation has led to a complex data landscape for health technologies and drug therapeutics developers, […]
News and Trends 20 Jul 2023
Endometrial cancer drug receives breakthrough therapy designation in China
HUTCHMED (China) Limited has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to the combination of fruquintinib and sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based […]
News and Trends 18 Jul 2023
FDA approves Beyfortus ahead of 2023-24 RSV season
The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The approval also covers children up to 24 months of age who remain vulnerable to severe […]
News and Trends 7 Jul 2023
FDA approves Alzheimer’s treatment
Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use. The decision makes LEQEMBI the first and only approved treatment shown to reduce the rate of disease progression […]
News and Trends 5 Jul 2023
Narcolepsy drug gets Chinese approval
RareStone Group, a rare disease-focused company aiming to establish the first rare disease ecosystem in China, has announced that the Chinese National Medical Products Administration (NMPA) has approved pitolisant (Wakix) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. In China, pitolisant is the first approved innovative drug for […]
News and Trends 4 Jul 2023
Innovent and IASO Bio obtain approval for CAR-T multiple myeloma treatment
Innovent Biologics, Inc. and IASO Biotechnology have announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) for FUCASO (Equecabtagene Autoleucel). FUCASO is the first fully-human BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior […]
ADVERTISEMENT
